Antibody Therapeutics Inc. has disclosed integrin receptor antagonists reported to be useful for the treatment of pulmonary fibrosis, renal fibrosis and hepatic fibrosis.
Cells have surface receptors called integrins that bind to repetitive domains present on the extracellular matrix (ECM) surrounding the cells, allowing them to grow and spread. A new study from the ...
MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results